Walleye Capital’s Ocular Therapeutix OCUL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$102K Sell
13,349
-188,433
-93% -$1.84M ﹤0.01% 5180
2026
Q2
$1.98M Sell
201,782
-539,360
-73% -$4.89M 0.01% 1528
2026
Q1
$6.28M Buy
741,142
+510,633
+222% +$4.87M 0.03% 657
2025
Q4
$2.8M Buy
230,509
+169,668
+279% +$2.06M 0.01% 1590
2025
Q3
$711K Buy
+60,841
New +$728K ﹤0.01% 2343
2025
Q1
– Sell
-10,548
Closed -$90.1K – 4869
2024
Q4
$90.1K Buy
+10,548
New +$103K ﹤0.01% 4180
2024
Q2
– Sell
-82,058
Closed -$747K – 5873
2024
Q1
$747K Buy
+82,058
New +$582K ﹤0.01% 2855
2023
Q3
– Sell
-43,665
Closed -$225K – 5190
2023
Q2
$225K Buy
43,665
+24,854
+132% +$148K ﹤0.01% 3006
2023
Q1
$99.1K Buy
+18,811
New +$89.3K ﹤0.01% 2935
2022
Q2
– Sell
-15,482
Closed -$77K – 2617
2022
Q1
$77K Sell
15,482
-55,973
-78% -$310K ﹤0.01% 1792
2021
Q4
$498K Buy
+71,455
New +$555K 0.02% 987
2020
Q3
– Sell
-34,700
Closed -$289K – 931
2020
Q2
$289K Buy
34,700
+23,700
+215% +$157K 0.06% 344
2020
Q1
$55K Buy
+11,000
New +$54.3K 0.01% 678

Other funds holding OCUL

Walleye Capital's OCUL Position: Q3 2026 in Review

Walleye Capital reduced its Ocular Therapeutix (OCUL) stake by 93% in Q3 2026, selling an estimated $1.84M and leaving 13,349 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #5180.

Walleye Capital first reported a position in OCUL in Q1 2020 and has held it in 13 quarters since. The position peaked at $6.28M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Walleye Capital held 13,349 shares of Ocular Therapeutix worth $102K as of Q3 2026.
  • Walleye Capital sold 188,433 Ocular Therapeutix shares in Q3 2026, an estimated $1.84M.
  • Ocular Therapeutix made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5180 holding.
  • Walleye Capital first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 13 quarters since.
  • Walleye Capital's Ocular Therapeutix position peaked at $6.28M in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.